uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors
October 21 2021 - 9:30AM
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced the appointment of Rachelle Jacques to its
Board of Directors. Ms. Jacques, who will serve on the Board’s
Audit Committee, has more than 25 years of industry experience in
strategic, cross-functional executive roles spanning finance,
business operations, manufacturing, and commercial. She has led
successful launches of several rare disease therapies including the
recent approval of a Regenerative Medicine Advanced Therapy
(RMAT)-designated product, one of only three since the program
inception in 2016.
"It is with great pleasure that we welcome
Rachelle to the uniQure board,” stated Matthew Kapusta, chief
executive officer of uniQure. “Her considerable biotechnology
experience, including her work in the rare disease space across
many functional areas, will be a valuable asset for uniQure as we
work to advance our pipeline candidates.”
“I am pleased with this opportunity to join the
uniQure Board of Directors at such an exciting time for the
Company,” stated Ms. Jacques. “I look forward to partnering with
Board members and providing consult to management as it prepares to
submit a BLA in hemophilia B, advances its Huntington’s disease
clinical program, and develops its pipeline of promising gene
therapy candidates.”
Since February 2019, Ms. Jacques has served as
the Chief Executive Officer of Enzyvant Therapeutics Inc, focusing
on the development of transformative regenerative therapies for
rare diseases. From August 2017 to February 2019, she served as the
Senior Vice President and Global Complement Franchise Head at
Alexion Pharmaceuticals, Inc., where she was responsible for global
franchise strategy development and execution across the therapeutic
areas of hematology, nephrology, and neurology. From January 2016
to June 2017, she was Vice President of U.S. Hematology Marketing
at Baxalta Inc. and then Shire plc, following Shire’s acquisition
of Baxalta in 2016. From July 2015 to June 2016, she served as Vice
President of Business Operations at Baxalta Inc. after its spinoff
from Baxter International Inc. Ms. Jacques held multiple leadership
positions at Baxter, including Vice President of Finance, U.S.
BioScience Business. Earlier in her career, Ms. Jacques served in
various roles at Dow Corning Corporation, including operational
management positions in the U.S., Europe, and China.
Ms. Jacques received her B.A. degree in business
administration from Alma College. She has also served as a
financial auditor for Ernst & Young and Deloitte and Touche.
Since April 2019, Ms. Jacques has served on the Board of Directors
of Corbus Pharmaceuticals (NASDAQ: CRBP), and from April 2020 to
February 2021, she served on the Board of Directors of Viela Bio.
She is co-chair of the Alliance for Regenerative Medicine (ARM)
Tissue Engineering & Biomaterials Committee and is a founding
member of the ARM Action for Equality Task Force.
About uniQure
uniQure is delivering on the promise of gene
therapy – single treatments with potentially curative results. We
are leveraging our modular and validated technology platform to
rapidly advance a pipeline of proprietary gene therapies to treat
patients with severe genetic diseases of the central nervous system
(CNS) and liver, including clinical programs in hemophilia B and
Huntington's disease and preclinical candidates in Fabry disease,
spinocerebellar ataxia Type 3, temporal lobe epilepsy, Alzheimer’s,
Parkinson’s, and ALS. www.uniQure.com
uniQure Contacts: |
|
|
FOR INVESTORS: |
|
FOR MEDIA: |
|
|
|
Maria E. Cantor |
Chiara E. Russo |
Tom Malone |
Direct: 339-970-7536 |
Direct: 617-306-9137 |
Direct: 339-970-7558 |
Mobile: 617-680-9452 |
Mobile: 617-306-9137 |
Mobile: 339-223-8541 |
m.cantor@uniQure.com |
c.russo@uniQure.com |
t.malone@uniQure.com |
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/e0201875-d1e1-446e-aab8-c9fbcc664b81
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From May 2024 to Jun 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Jun 2023 to Jun 2024